Remegen Co

Remegen Co., a pharmaceutical preparation manufacturer headquartered in China, has reported its carbon emissions for the years 2020 to 2024. The company's reported emissions primarily cover Scope 1 and Scope 2.

In the most recent reporting year, 2024, Remegen Co. reported a total of approximately 59,153,380 kg CO2e. This figure comprises approximately 54,150 kg CO2e from Scope 1 emissions and about 59,099,230 kg CO2e from Scope 2 emissions.

For the preceding year, 2023, the company's total emissions were approximately 70,195,760 kg CO2e, with Scope 1 contributing around 95,770 kg CO2e and Scope 2 accounting for approximately 70,100,000 kg CO2e.

In 2022, Remegen Co. reported total emissions of approximately 39,551,550 kg CO2e, all of which were attributed to Scope 2 emissions, with no reported Scope 1 emissions for that year.

For 2021, total emissions stood at approximately 22,183,040 kg CO2e, also entirely from Scope 2. In 2020, the company reported Scope 1 emissions of approximately 4,136,080 kg CO2e and Scope 2 emissions of approximately 12,278,120 kg CO2e, resulting in a combined total of approximately 16,414,190 kg CO2e for these scopes.

Remegen Co. has established several climate commitments. The company has a near-term target to reduce CO2 emissions by 0.6% annually between 2020 and 2025, aiming for a 3.1% reduction in total emissions by 2025 compared to 2020 levels, without increasing the overall volume of greenhouse gas emissions. Looking further ahead, Remegen Co. has a long-term commitment to reduce CO2 emissions by 0.4% per year from 2025 to 2030, with the objective of achieving a 3% reduction in total carbon emissions by 2035. It is important to note that the company has not disclosed Scope 3 emissions data.